Adipome biomarkers in obese TNBC mice for targeted therapy
Official title: Identifying Predictive and Prognostic Adipome Biomarkers in Obese TNBC Mice for Targeted Therapy Development
Funded at Hackensack University Medical Center · NIH-11457952 · Data updated 2026-11-12
A study in mice explores how fat-derived particles called adipomes influence an aggressive breast cancer type, with the goal of guiding personalized therapies.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | July 16, 2026 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $460,254 |
| NIH project number | 1R21CA309638-01A1 |
| Project ID | NIH-11457952 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with obesity who are at risk for or have TNBC, or patients contributing tissue/plasma samples for related studies.
✕Less likely to help
Early-stage animal and lab studies may not yet translate to direct benefits for patients.
What this research studies
This project uses a mouse model of triple-negative breast cancer to identify fat-cell–derived extracellular vesicles that may drive cancer spread. It looks at how these adipomes differ in obese versus lean conditions and how their lipid cargo affects cancer and nearby breast cells. The work also examines how exposure to adipomes changes gene activity and methylation in cancer and non-cancer cells, seeking mechanisms that link obesity to worse cancer outcomes. Findings could point to new therapeutic targets that counteract adipome-driven progression in TNBC.
Why it matters
Potential benefit: If successful, the research could inform new strategies to treat TNBC in patients with high body fat or obesity.
How similar studies have gone: Previous work has linked adipose-derived factors to cancer progression in preclinical models, but this project advances understanding in TNBC specifically.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Nagajyothi, Jyothi Falguni — Hackensack University Medical Center
- Study coordinator: Nagajyothi, Jyothi Falguni
Related research
Other NIH-funded projects on the same topics.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
-
Metabolic imaging to guide targeted therapy for liver cancer
A clinician-scientist at UPenn is pursuing training to use metabolic imaging to tailor therapy for hepatocellular carcinoma.
-
Metabolic-driven stem cells and inflammatory niches in early-onset colorectal cancer
Researchers are studying how metabolic changes from obesity and diet may fuel early-onset colorectal cancer by linking stem cell biology and inflammation in patients.
-
Targeted therapy for splicing-factor mutant myeloid cancers
Aims to test a dual drug strategy targeting ATR and PARP pathways in adults with splicing-factor mutant acute myeloid leukemia or related myeloid diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.